Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ACUPHARMA ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   13.9% 13.3% 12.5% 13.4% 20.1% 15.7% 17.7% 17.7%   Credit score (0-100)   17 18 18 16 5 11 9 9   Credit rating   BB BB BB BB B BB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 -0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,724 1,684 1,368 1,185 778 1,128 0.0 0.0   EBITDA   245 369 13.1 277 -206 404 0.0 0.0   EBIT   112 183 -172 103 -318 300 0.0 0.0   Pre-tax profit (PTP)   11.9 43.7 -299.3 8.4 -420.1 153.2 0.0 0.0   Net earnings   5.2 32.8 -234.6 6.0 -449.6 153.2 0.0 0.0   Pre-tax profit without non-rec. items   11.9 43.7 -299 8.4 -420 153 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Tangible assets total   268 234 148 90.3 141 105 0.0 0.0   Shareholders equity total   154 387 152 158 -291 -138 -438 -438   Interest-bearing liabilities   1,455 1,265 1,321 1,047 997 1,044 527 527   Balance sheet total (assets)   3,258 3,292 2,550 2,397 2,011 2,103 89.1 89.1   Net Debt   1,425 1,235 1,316 1,045 995 1,043 527 527     See the entire balance sheet 1000.0 Volume  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,724 1,684 1,368 1,185 778 1,128 0.0 0.0   Gross profit growth   13.9% -2.3% -18.8% -13.4% -34.3% 44.9% -100.0% 0.0%   Employees   4 4 3 3 2 2 0 0   Employee growth %   0.0% 0.0% -25.0% 0.0% -33.3% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,258 3,292 2,550 2,397 2,011 2,103 89 89   Balance sheet change%   23.3% 1.0% -22.5% -6.0% -16.1% 4.6% -95.8% 0.0%   Added value   244.9 368.5 13.1 277.1 -143.2 404.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   274 -111 -370 -326 -66 -213 -105 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 -1.0 1.0 -1.0 1.0 0.0 0.0   1000.0 Profitability  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   6.5% 10.8% -12.6% 8.7% -40.8% 26.6% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   4.1% 5.6% -5.9% 4.2% -13.5% 13.2% 0.0% 0.0%   ROI %   10.0% 11.0% -10.9% 7.7% -28.9% 29.4% 0.0% 0.0%   ROE %   3.4% 12.1% -87.0% 3.9% -41.5% 7.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Equity ratio %   4.7% 11.7% 6.0% 6.6% -12.7% -6.2% -83.1% -83.1%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   581.7% 335.1% 10,028.3% 376.9% -482.5% 257.9% 0.0% 0.0%   Gearing %   944.9% 326.9% 868.0% 661.4% -342.2% -756.1% -120.3% -120.3%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   10.5% 10.2% 9.9% 8.0% 10.0% 14.4% 0.0% 0.0%   1000.0 Liquidity  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Quick Ratio   0.6 0.5 0.5 0.6 0.5 0.7 0.0 0.0   Current Ratio   1.0 0.9 0.9 0.9 0.8 0.9 0.0 0.0   Cash and cash equivalent   30.3 29.5 5.1 2.1 1.7 1.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -95.2 -161.8 -303.1 -145.2 -569.2 -306.6 -263.6 -263.6   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   61 92 4 92 -72 202 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   61 92 4 92 -103 202 0 0   EBIT / employee   28 46 -57 34 -159 150 0 0   Net earnings / employee   1 8 -78 2 -225 77 0 0